(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 February 2017 (09.02.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/023660 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2016/044359

(22) International Filing Date:
28 July 2016 (28.07.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/199,563 31 July 2015 (31.07.2015) US
62/287,518 27 January 2016 (27.01.2016) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(72) Inventors: **ZIMMERMANN, Tracy**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **CHAN, Amy**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **JADHAV, Vasant**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **MAIER, Martin**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **RAJEEV, Kallanthottathil, G.**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US).

(74) Agents: **ZACHARAKIS, Maria, Laccotripe** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES

(57) **Abstract**: The present invention provides iRNA agents, *e.g.*, double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

WO 2017/023660 A1